Dual-ligand modified liposomes provide effective local targeted delivery of lung-cancer drug by antibody and tumor lineage-homing cell-penetrating peptide

Drug Delivery

Volumn 25, Issue 1, 2018, Pages 256-266

  Lin, Congcong ^a   Zhang, Xue ^a   Chen, Hubiao ^a   Bian, Zhaoxiang ^a   Zhang, Ge ^a   Riaz, Muhammad Kashif ^a   Tyagi, Deependra ^a   Lin, Ge ^b   Zhang, Yanbo ^c   Wang, Jinjin ^a   Lu, Aiping ^a   Yang, Zhijun ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Carbonic anhydrase IX; Dual ligand liposomes; Orthotopic lung cancer model; Pulmonary delivery; Tumor lineage homing cell penetrating peptide

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONIC ANHYDRASE IX ANTIBODY; CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE 33; LIGAND; LIPOSOME; MACROGOL 2000; MALEIMIDE; MONOCLONAL ANTIBODY; TRIPTOLIDE; UNCLASSIFIED DRUG; ANTIBODY; CARBONATE DEHYDRATASE IX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS ASSAY; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MALE; MOUSE; NANOENCAPSULATION; NON SMALL CELL LUNG CANCER; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; SYSTEMIC CIRCULATION; TUMOR SPHEROID; WOUND HEALING ASSAY; A-549 CELL LINE; ADMINISTRATION AND DOSAGE; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; LUNG TUMOR; METABOLISM; MULTICELLULAR SPHEROID; NUDE MOUSE; PHARMACOKINETICS; PROCEDURES; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

A549 CELLS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS; CARBONIC ANHYDRASE IX; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LIGANDS; LIPOSOMES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SPHEROIDS, CELLULAR;

EID: 85047819292     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.1080/10717544.2018.1425777     Document Type: Article

References (41)

1. Al-Ahmady ZS, Chaloin O, Kostarelos K. (2014). Monoclonal antibody-targeted, temperature-sensitive liposomes: in vivo tumor chemotherapeutics in combination with mild hyperthermia. J Control Release 196:332–43.
2. Bae YH, Park K. (2011). Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 153:198–205.
3. Cai D, Gao W, He B, et al. (2014a). Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials 35:2283–94.
4. Cai DF, Gao W, He B, et al. (2014b). Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy. Biomaterials 35:2283–94.
5. Chen LM, Liu Q, Huang ZH, et al. (2012a). Tripchlorolide induces cell death in lung cancer cells by autophagy. Int J Oncol 40:1066–70.
6. Chen XY, Huang WH, Wong BCK, et al. (2012b). Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery. Int J Nanomedicine 7:1139–48.
7. Chereddy KK, Her CH, Comune M, et al. (2014). PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing. J Control Release 194:138–47.
8. Dicheva BM, Ten Hagen TL, Schipper D, et al. (2014). Targeted and heattriggered doxorubicin delivery to tumors by dual targeted cationic thermosensitive liposomes. J Control Release 195:37–48.
9. Fonseca SB, Pereira MP, Kelley SO. (2009). Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 61:953–64.
10. Garbuzenko OB, Saad M, Pozharov VP, et al. (2010). Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA 107:10737–42.
11. Gill KK, Nazzal S, Kaddoumi A. (2011). Paclitaxel loaded PEG(5000)-DSPE micelles as pulmonary delivery platform: formulation characterization, tissue distribution, plasma pharmacokinetics, and toxicological evaluation. Eur J Pharm Biopharm 79:276–84.
12. Kaminskas LM, Mcleod VM, Ryan GM, et al. (2014). Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release 183:18–26.
13. Kondo E, Saito K, Tashiro Y, et al. (2012). Tumour lineage-homing cell-penetrating peptides as anticancer molecular delivery systems. Nat Commun 3:951.
14. Koshkina NV, Waldrep JC, Roberts LE, et al. (2001). Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7:3258–62.
15. Le QT, Chen E, Salim A, et al. (2006). An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 12:1507–14.
16. Li XF, Zang AM, Jia YC, et al. (2016). Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21. Mol Med Rep 13:2763–8.
17. Liang DS, Su HT, Liu YJ, et al. (2015). Tumor-specific penetrating peptides- functionalized hyaluronic acid-d-alpha-tocopheryl succinate based nanoparticles for multi-task delivery to invasive cancers. Biomaterials 71:11–23.
18. Liao SY, Aurelio ON, Jan K, et al. (1997). Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57:2827–31.
19. Lin C, Wong BCK, Chen H, et al. (2017). Pulmonary delivery of triptolideloaded liposomes decorated with anti-carbonic anhydrase IX antibody for lung cancer therapy. Sci Rep 7:1097.
20. Liu YY, Ran R, Chen JT, et al. (2014). Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting. Biomaterials 35:4835–47.
21. Luo T, Loira-Pastoriza C, Patil HP, et al. (2016). PEGylation of paclitaxel largely improves its safety and anti-tumor efficacy following pulmonary delivery in a mouse model of lung carcinoma. J Control Release 239:62–71.
22. Maeda H, Nakamura H, Fang J. (2013). The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. Adv Drug Deliv Rev 65:71–9.
23. Mahmoud W, Rousserie G, Reveil B, et al. (2011). Advanced procedures for labeling of antibodies with quantum dots. Anal Biochem 416:180–5.
24. Mcdonald PC, Winum JY, Supuran CT, Dedhar S. (2012). Recent developments in targeting carbonic anhydrase IX for cancer therapeutics. Oncotarget 3:84–97.
25. Mehta G, Hsiao AY, Ingram M, et al. (2012). Opportunities and challenges for use of tumor spheroids as models to test drug delivery and efficacy. J Control Release 164:192–204.
26. Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer 6:583–92.
27. Pastorek J, Pastorekova S. (2015). Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: From biology to clinical use. Sem Cancer Biol 31:52–64.
28. Raghunand N, Gatenby RA, Gillies RJ. (2003). Microenvironmental and cellular consequences of altered blood flow in tumours. Br J Radiol 76: S11–S22.
29. Reno TA, Kim JY, Raz DJ. (2015). Triptolide inhibits lung cancer cell migration, invasion, and metastasis. Ann Thorac Surg 100:1817–25.
30. Saarnio J, Parkkila S, Parkkila AK, et al. (1998). Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153:279–85.
31. She Z, Zhang T, Wang X, et al. (2014). The anticancer efficacy of pixantrone- loaded liposomes decorated with sialic acid-octadecylamine conjugate. Biomaterials 35:5216–25.
32. Swinson DEB, Jones JL, Richardson D, et al. (2003). Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. J Clin Oncol 21:473–82.
33. Vermylen P, Roufosse C, Burny A, et al. (1999). Carbonic anhydrase IX antigen differentiates between preneoplastic malignant lesions in non-small cell lung carcinoma. Eur Respir J 14:806–11.
34. Wang FH, Wang Y, Zhang X, et al. (2014). Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release 174:126–36.
35. Wauthoz N, Deleuze P, Hecq J, et al. (2010). In vivo assessment of temozolomide local delivery for lung cancer inhalation therapy. Eur J Pharm Sci 39:402–11.
36. Wong BCK, Zhang HQ, Qin L, et al. (2014). Carbonic anhydrase IXdirected immunoliposomes for targeted drug delivery to human lung cancer cells in vitro. Drug Des Devel Ther 8:993–1001.
37. Wykoff CC, Beasley N, Watson PH, et al. (2001). Expression of the hypoxia- inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 158:1011–19.
38. Xue M, Zhao Y, Li XJ, et al. (2012). Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs. free triptolide in rats. Eur J Pharm Sci 47:713–17.
39. Yang YF, Yang Y, Xie XY, et al. (2014). PEGylated liposomes with NGR ligand and heat-activable cell-penetrating peptidedoxorubicin conjugate for tumor-specific therapy. Biomaterials 35:4368–81.
40. Yao VJ, D’angelo S, Butler KS, et al. (2016). Ligand-targeted theranostic nanomedicines against cancer. J Control Release 240:267–86.
41. Zhuang XM, Liu PX, Zhang YJ, et al. (2013). Simultaneous determination of triptolide and its prodrug MC002 in dog blood by LC-MS/MS and its application in pharmacokinetic studies. J Ethnopharmacol 150:131–7.